胰腺癌影像学、分期及新辅助治疗前后PACT-UK放射学模板应用更新
本文综述胰腺导管腺癌的影像学评估,重点包括新辅助治疗前后的肿瘤分期与血管评估、结构化报告及PACT-UK放射学模板的应用,以及人工智能在诊断和分期中的潜在未来作用;指出胰腺协议CT是分期的主要影像 modality,新辅助治疗后因缺乏稳健的放射学标准来预测反应和区分治疗所致纤维化/炎症与残留肿瘤而评估困难。
要点
- 胰腺协议CT是疑似胰腺肿瘤分期的主要影像学方法,其他模态作为解决问题工具。
- 新辅助治疗后影像评估困难,因缺乏稳健的放射学标准来预测反应和区分纤维化/炎症与残留肿瘤。
- 本文介绍PACT-UK放射学结构化报告模板用于胰腺癌分期。
核心结论
- 胰腺导管腺癌预后仍差,新辅助治疗带来一定希望;影像评估需特定方法,胰腺协议CT是分期主要模态,新辅助治疗后评估因缺乏稳健放射学标准而尤其困难;本文重点更新分期(含血管评估)、PACT-UK结构化报告模板及人工智能的潜在未来作用。
研究设计与样本
- 综述,检索范围与纳入文献原文未报告。
局限性
- 原文指出当前缺乏稳健的放射学标准来预测新辅助治疗反应及区分治疗所致纤维化/炎症与残留肿瘤。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Pancreatic ductal adenocarcinoma continues to have a poor prognosis, although recent advances in neoadjuvant treatments (NATs) have provided some hope. Imaging assessment of suspected tumours can be challenging and requires a specific approach, with pancreas protocol CT being the primary imaging modality for staging with other modalities used as problem-solving tools to facilitate appropriate management. Imaging assessment post NAT can be particularly difficult due to a current lack of robust radiological criteria to predict response and differentiate treatment induced fibrosis/inflammation from residual tumour. This review aims to provide an update of pancreatic ductal adenocarcinoma with particular focus on three points: tumour staging pre- and post-NAT including vascular assessment, structured reporting with introduction of the PAncreatic Cancer reporting Template-UK (PACT-UK) radiology template, and the potential future role of artificial intelligence in the diagnosis and staging of pancreatic cancer.
引用
- Corallo C, Al-Adhami AS, Jamieson N, et al. An update on pancreatic cancer imaging, staging, and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment. Br J Radiol. 2025. PMID: 39460945. doi:10.1093/bjr/tqae217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。